Rapidly evolving cancer diagnostics company AMLo Biosciences have just received the UKCA marker for their patented melanoma test, AMBLor®. This means that AMBLor® can now be marketed and used by the NHS and private healthcare professionals throughout the UK.

Simply put, AMBLor® helps to detect the presence of biomarkers which identify if patients are at low risk from the spread of skin cancers, focusing on melanoma which is the UK’s fifth most common cancer.

Only a small percentage of melanomas progress beyond early stage, but all are treated as if the risk of recurrence is the same. The aim of the easy-to-use test is to aid in identifying those with a low risk of melanoma progression, which could spare a sector of patients from further diagnostic procedures and minimize the anxiety created during follow-up, allowing clinicians to focus on those cases which are genuinely at risk of spread and achieve better outcomes for patients.

The impact onto waiting lists should ease the burden on over-stretched health services, making diagnosis and treatment streamlined and more effective with an estimated saving of over £10,000 per 100 NHS melanoma patients.

The opening up of the product to the UK health sector will allow AMLo Biosciences to accelerate revenue.

The company is also now supplying to the US, meaning that AMLo has a prime opportunity to take the product to the global market, positive news regarding a condition that affects over 300,000 people worldwide.

Northstar Ventures have been working with AMLo Biosciences since its inception and the organisation is part of the Northstar portfolio of companies.

https://amlo-biosciences.com/amblor-receives-ukca-mark/

For more information contact Alex Buchan, Investment Director: [email protected]